Showing 2461-2470 of 2652 results for "".
- Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-present-late-breaking-data-from-phase-3-studies-of-investigational-abicipar-pegol-in-wet-amd/2476996/Allergan and Molecular Partners announced 2-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with wet age-related macular degeneration (AMD). In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains c
- Alcon Celebrates World Sight Day, Strengthens Commitment to Enhancing Global Access to Eye Carehttps://modernod.com/news/alcon-celebrates-world-sight-day-strengthens-commitment-to-enhancing-global-access-to-eye-care/2476983/Thousands of Alcon associates worldwide are participating in activities to support the advancement of eye health in honor of World Sight Day. To celebrate the occasion, the company announced a theme for the upcoming year, “Alcon: The Official Sponsor of 20/20,” which is designed to highlight its
- Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstenthttps://modernod.com/news/ivantis-completes-enrollment-of-international-spectrum-registry-for-hydrus-microstent/2476973/Ivantis announced that it has completed enrollment in its SPECTRUM, which the company calls the largest single-device registry in ophthalmology. SPECTRUM is a patient registry for the Hydrus Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with mild to moderate
- Orbis International Calls for “All Eyes on 2020” and Preserving the Future of Visionhttps://modernod.com/news/orbis-international-calls-for-all-eyes-on-2020-and-preserving-the-future-of-vision/2476963/On the eve of World Sight Day, Orbis International is celebrating achievements of the eye health community over the past two decades, and warns of a projected global tripling in demand for eye care over the next 30 years. 2020 is a critical year for Orbis International and other leaders in
- Optovue to Introduce NetVue Cloud Image Management Solutions at AAOhttps://modernod.com/news/optovue-introduces-netvue-cloud-image-management-solutions-at-aao/2476940/Optovue announced it will introduce NetVue Cloud image management software at the annual AAO meeting in San Francisco. The NetVue software provides quick access to patients’ images and data on a single screen, eliminating the need to open device-specific app
- On World Sight Day, Orbis International Calls for “All Eyes on 2020” and Preserving the Future of Visionhttps://modernod.com/news/on-world-sight-day-orbis-international-calls-for-all-eyes-on-2020-and-preserving-the-future-of-vision/2476936/Today, Orbis International commemorates World Sight Day by celebrating achievements of the eye health community over the past two decades, and warning of a projected global tripling of blindness over the next 30 years. Next year is a critical year for Orbis International and other leaders
- GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase 3 Trial of GS010 for the Treatment of LHONhttps://modernod.com/news/gensight-biologics-reports-sustained-efficacy-and-safety-at-96-weeks-in-rescue-phase-3-trial-of-gs010-for-the-treatment-of-lhon/2476910/GenSight Biologics reported the first set of results from week 96 of the RESCUE phase 3 clinical trial, which evaluated the efficacy and safety of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditary Optic Neuropat
- Novo Nordisk’s Rybelsus Gains FDA Approval as First Oral GLP-1 Receptor Agonist for Type 2 Diabeteshttps://modernod.com/news/novo-nordisks-rybelsus-gains-fda-approval-as-first-oral-glp-1-receptor-agonist-for-type-2-diabetes/2476907/The FDA announced Friday the approval of Novo Nordisk’s Rybelsus (semaglutide) to improve control of blood glucose in adults with type 2 diabetes, along with diet and exercise, making it the first oral GLP-1 receptor agonist cleared in the US. Lisa Yanoff, acting director of the Division of
- Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to DME or RVOhttps://modernod.com/news/graybug-vision-initiates-clinical-trial-in-macular-edema-secondary-to-dme-or-rvo/2476898/Graybug Vision announced the initiation of its phase 2a study with GB-102 in patients with macular edema (ME) secondary to diabetic macular edema (DME) or retinal vein occlusion (RVO). GB-102, a pan-Vascular Endothelial Growth Factor (VEGF) inhibitor and potential twice-per-year therapy is
- Oyster Point Pharma Expands Executive Leadership Teamhttps://modernod.com/news/oyster-point-pharma-expands-executive-leadership-team/2476896/Oyster Point Pharma announced the appointment of Dan Lochner, MBA, as its Chief Financial Officer, and John Snisarenko, MBA, as Chief Commercial Officer. Mr. Lochner joins Oyster Point Pharma after spending nearly 15 years, most recently as a Managing Director, at Goldman Sachs asset mana